Bivalirudin Plus High-Dose Infusion Versus Heparin Monotherapy in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Fibrinolysis: a Randomized Trial

This multicenter, randomized controlled trial in China aims to enroll 2,400 patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) within 24 hours post-fibrinolysis. Participants will be randomly assigned in a 1:1 ratio to receive either bivalirudin or heparin, with follow-up at 30 days and 1 year. The primary endpoint is a composite of all-cause mortality and Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at 30 days.

Start Date01 May 2025

Sponsor / Collaborator

The First Affiliated Hospital of Xi'an Jiaotong University

CTRI/2024/11/077189

/ Not yet recruitingPhase 4IIT

Randomized controlled trial of Heparin Vs Bivalirudin anticoagulation in neonates and infants undergoing Arterial switch operation on integrated ECMO-CPB circuit

Start Date24 Dec 2024

Sponsor / Collaborator

All India Institute of Medical Sciences

NCT06275555

/ Not yet recruitingNot ApplicableIIT

Efficacy and Safety of Bivalirudin Versus Heparin in Anticoagulant Therapy of ECMO: a Randomized Controlled Trial

The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.

Start Date01 Aug 2024

Sponsor / Collaborator

Beijing Anzhen Hospital

100 Clinical Results associated with Bivalirudin

100 Translational Medicine associated with Bivalirudin

100 Patents (Medical) associated with Bivalirudin

2,294

Literatures (Medical) associated with Bivalirudin

01 May 2025·International Journal of Biological Macromolecules

The derivatives of hirudin-like peptides from the Poecilobdella manillensis exhibit antithrombotic and anti-ischemic stroke effects

Article

Author: Zhou, Shengwen ; Tadese, Dawit Adisu ; Duan, Zilei ; Lai, Ren ; Asmamaw, Demeke ; Yang, Juan ; Mwangi, James ; Michira, Brenda B ; Lv, Qiumin ; Chen, Qian ; Khalid, Mehwish ; Chen, Yifan

Almost all currently approved anticoagulants interfere with hemostasis and increase the risk of bleeding complications. Thus, there is a critical need for safer anti-thrombotic drugs without bleeding risk. Hirudin has demonstrated potent antithrombotic properties, but is clinically limited due to its high bleeding risk. Hirudin variants such as bivalirudin have been developed to address this issue, yet present a similar proportional risk of bleeding. In this study, several hirudin-like peptides were identified from the salivary gland transcriptome of Poecilobdella manillensis. Guided by the structural design principles of bivalirudin, derivatives of these hirudin-like peptides were synthesized and evaluated for their antithrombotic efficacy and safety in thrombosis and ischemic stroke. Results suggested that derived peptides PM3, PM4, PM6 and PM7 can effectively inhibited the activity of thrombin in vitro. Furthermore, PM4, PM6 and PM7 exhibited robust anticoagulant activity in vivo. Importantly, PM4 and PM7 exhibited significantly lower bleeding risk compared to bivalirudin, as well as comparable efficacy in mitigating intracerebral thrombosis in a transient middle cerebral artery occlusion mouse model, without inducing intracerebral hemorrhage. These findings highlight the therapeutic potential of hirudin-like peptide derivatives as promising candidates for the treatment of thrombosis and ischemic stroke, combining efficacy with an improved safety profile.

01 May 2025·Journal of Cardiothoracic and Vascular Anesthesia

Heparin Versus Bivalirudin in Pediatric Patients Assisted With Mechanical Circulatory Support: A Retrospective Before-and-after Study

Article

Author: Ricci, Zaccaria ; Benegni, Simona ; Olimpieri, Alessandro ; Rizza, Alessandra ; Vallesi, Leonardo ; Cantarutti, Nicoletta ; Brancaccio, Gianluca ; Amodeo, Antonio ; Felice, Giovina Di ; Favia, Isabella ; Giorni, Chiara ; Chiara, Luca Di

OBJECTIVESChildren assisted with mechanical circulatory support experience bleeding and thrombotic complications that may depend upon anticoagulation strategies. The primary aim of this study was to compare the incidence of thrombotic events in pediatric heart failure patients assisted with mechanical circulatory support with the use of bivalirudin versus heparin anticoagulation. A secondary aim was to compare the percentage of out-of-range partial thromboplastin time values between these anticoagulants.DESIGNRetrospective cohort study.SETTINGTertiary pediatric cardiac intensive care unit.PARTICIPANTSPediatric patients undergoing mechanical circulatory support for cardiac failure.INTERVENTIONSNone.MEASUREMENTS AND MAIN RESULTSA total of 36 pediatric patients on mechanical support treated with either heparin (n.18) or bivalirudin (n.18) during the first 30 days of intensive care unit admission were compared. Bivalirudin group data were retrieved from February 2018 to August 2020 while data on the heparin group were extrapolated from 2015 to 2017. A comparison of anticoagulation was conducted specifically in EXCOR Berlin Heart and extracorporeal membrane oxygenation patients. Berlin Heart patients showed 1 (12.5%) versus 8 (80%) thrombotic episodes in the bivalirudin and heparin groups, respectively (p = 0.005), 0 and 3 (30%) cerebrovascular events, and 0 versus 3 (30%) death episodes, respectively (p = 0.054). In extracorporeal membrane oxygenation patients, the bivalirudin and heparin groups showed 0 versus 1 (8.3%) patient with a thrombosis episode (p = 0.40), 0 and 0 cerebrovascular events, and 5 (50%) versus 3 (25%) death episodes, respectively (p = 0.169). The number of out-of-range partial thromboplastin time values was higher in the heparin group both in Berlin Heart and extracorporeal membrane oxygenation patients (p < 0.0001).CONCLUSIONSIn a cohort of children with heart failure, bivalirudin use was associated with a reduction in thrombotic events in Berlin Heart patients compared with heparin over a period of 30 days.

01 May 2025·JHLT Open

Anticoagulation Management During ECMO: Narrative Review

Review

Author: Vajter, Jaromir ; Volod, Oksana

Extracorporeal membrane oxygenation (ECMO) is a critical intervention for patients with severe respiratory or cardiac failure, requiring careful management of anticoagulation to prevent thromboembolic complications. This review examines current practices and challenges in ECMO anticoagulation, focusing on strategies, agents, and emerging insights. Unfractionated heparin (UFH) remains the most commonly used anticoagulant, monitored via activated partial thromboplastin time (aPTT) or activated clotting time (ACT). Increasing attention is given to alternative tools like anti-Xa and viscoelastic assays (VEA), which offer potentially more reliable results. Supplementation with antithrombin should be considered if levels fall below 50%-70% to optimize heparin efficacy. Low molecular weight heparin (LMWH) is occasionally used due to its predictable pharmacokinetics, though challenges in dosing and reversal limit its application. Direct thrombin inhibitors, such as bivalirudin, are valuable alternatives, particularly for patients with heparin-induced thrombocytopenia (HIT), though their cost and availability remain barriers. Anticoagulation in ECMO patients is complex, balancing the risks of thrombosis and bleeding. Factors such as patient age, underlying conditions, and ECMO-induced coagulopathies complicate management. Personalized anticoagulation protocols and point-of-care VEA are emerging as effective tools for improving therapy. Routine no-anticoagulation strategies are not recommended unless there are significant bleeding complications. Ongoing research into novel anticoagulants and the long-term impact of anticoagulation on ECMO outcomes is critical. Anticoagulation management in ECMO continues to evolve, focusing on individualized approaches, improved monitoring, and better outcomes. Standardized protocols and further research are essential for optimizing care in this high-risk population.

News (Medical) associated with Bivalirudin

10 Dec 2024

·www.globenewswire.com

CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

Industry veterans John Maraganore, Ph.D., and Rachel Meyers, Ph.D., to provide strategic guidance on the company’s RNA Actuating platform to develop a new class of RNA medicines that upregulate protein coding genesCAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company’s programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi therapeutics, ONPATTRO®, GIVLAARI®, OXLUMO®, and LEQVIO®. Additionally, Dr. Meyers brings more than two decades of life sciences leadership, research, and development experience in RNA-based medicines, having spent nearly 14 years at Alnylam where she most recently served as Senior Vice President of Research and RNAi Lead Development. She currently sits on the company’s Scientific Advisory Board. “We feel privileged and are delighted to welcome Drs. Maraganore and Meyers to our CAMP4 team as strategic advisors,” said Josh Mandel-Brehm, Chief Executive Officer of CAMP4. “We view their joining the team as a testament to the promise and potential of our approach for upregulating gene expression to potentially address a broad range of diseases. As we prepare for 2025, we look forward to benefiting from their insights and expertise as we advance our efforts in bringing potentially transformative RNA medicines to patients in need of disease-modifying solutions.” Dr. Maraganore added, “The targeted upregulation of gene expression has been a long-standing challenge for the field, and by applying established and clinically validated antisense oligonucleotide technology to groundbreaking science, CAMP4 could potentially make a meaningful impact on patients across a broad range of diseases. I look forward to working with them as they pioneer the field of upregulation.” Prior to his role at Alnylam, Dr. Maraganore led the product franchises in oncology, cardiovascular, inflammatory, and metabolic diseases for Millennium Pharmaceuticals, in addition to leadership of M&A, strategy, and biotherapeutics. Earlier in his career, Dr. Maraganore invented and spearheaded the development of ANGIOMAX® (bivalirudin) for injection while at Biogen and was also a scientist at ZymoGenetics, Inc., and the Upjohn Company. He currently serves as a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Ventures, an Executive Partner at RTW Investments, a Senior Advisor for Blackstone Life Sciences, and a Senior Advisor for Jeffries Financial Group. Beyond his leadership roles in the investment community, Dr. Maraganore also sits on the Board of Directors for multiple publicly traded companies, including Beam Therapeutics, Kymera Therapeutics, Rapport Therapeutics, and Takeda Pharmaceuticals. He received his B.A., M.S., and Ph.D. in biochemistry and molecular biology at the University of Chicago. Dr. Meyers currently serves as a member of the Board of Directors of Korro Bio (Nasdaq: KRRO), a biopharmaceutical company focused on discovering, developing, and commercializing a new class of genetic medicines based on editing RNA, and also holds a variety of advisory roles within the biotech community. Most recently, she served as Founder and Chief Scientific Officer at Faze Medicines, a Third Rock Ventures-spawned biotech company focused on treating diseases of high unmet need through the perturbation of biomolecular condensates. Earlier in her career, Dr. Meyers was a senior scientist at Millennium Pharmaceuticals and today serves on multiple scientific advisory boards, including the National Advisory Board on Innovation and Entrepreneurship through the Department of Commerce. Furthermore, she is listed as an inventor on numerous patents and patent applications and has authored many peer-reviewed publications. Dr. Meyers received her postdoctoral training with Lew Cantley at Harvard Medical School in signal transduction and earned her Ph.D. in biology from Nobel laureate Phil Sharp at the Massachusetts Institute of Technology in in vitro transcription. She earned her BA in Biochemistry from Brandeis University. “I’ve had the unique opportunity to work alongside tremendously talented professionals who have led the shaping of the RNA medicines space,” said Dr. Meyers. “Having been at the forefront of these scientific breakthroughs, I believe now more than ever RNA-based therapies are poised to continue transforming how we treat patients with complex diseases. Having the opportunity to advise CAMP4 as they continue advancing the field is an extension of the work to which I’ve committed my career.” About CAMP4 Therapeutics CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regRNAs, which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform™ enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. Learn more about us at www.CAMP4tx.com and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning CAMP4’s plans, objectives, expectations and intentions; the timing and results of ongoing and future clinical trials, including expectations on the timing of reporting SAD and MAD data from and seeking regulatory approval for the CMP-CPS-001 trial; its growth strategy; and cash balance guidance. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company’s current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company’s ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of the Company’s product candidates, which is complex, and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates or any future product candidates the Company may develop; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of the Company’s suppliers; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as well as other information we file with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contacts Investor Relations:Sandya von der WeidLifeSci Advisorssvonderweid@lifesciadvisors.com Media:Jason Braco, Ph.D.LifeSci Communicationsjbraco@lifescicomms.com

Executive ChangeOligonucleotide

23 Sep 2024

·www.businesswire.com

Avenacy to Share Company’s Year One Progress at CPHI Milan 2024

SCHAUMBURG, Ill.--( BUSINESS WIRE )--Avenacy, a specialty pharmaceutical company focused on supplying critical medications, looks forward to celebrating its first year of growth and success since launching in October 2023. Backed by a robust global network of development and FDA-inspected contract manufacturing partners, Avenacy has already brought 13 injectable products to the U.S. market to address key gaps in the drug supply chain. “We are incredibly proud of the achievements and progress we have made at Avenacy since launching nearly a year ago as a trusted partner and provider of critical injectable medicines for the U.S. healthcare system,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “We have acted swiftly and decisively to bring over a dozen medications to the U.S. market to help meet the needs of patients, strengthened our financial position with the addition of esteemed pharmaceutical investor and businessman, Dr. Patrick Soon-Shiong, and built out our infrastructure and leadership to support scaling up our business. As we look to usher in the next phase of growth for Avenacy, we will remain steadfast in our goal of enhancing patient care and enabling access to safe, high-quality essential medications.” Through a rigorous and optimized selection process, Avenacy has launched thirteen products in the U.S. market, including: Melphalan Hydrochloride for Injection Bivalirudin for Injection Fosaprepitant for Injection Fulvestrant Injection Furosemide for Injection Desmopressin Acetate for Injection Eptifibatide for Injection Magnesium Sulfate in Water for Injection Isoproterenol Hydrochloride Injection, USP Tranexamic Acid Injection, USP Prochlorperazine Edisylate Injection, USP Palonosetron Hydrochloride Injection, USP Metoclopramide Injection, USP The Company is well-positioned to continue expanding its differentiated portfolio to meet the needs of today’s dynamic drug supply chain while ensuring quality of care to patients. All of Avenacy’s products feature unique packaging and labeling designed to assist healthcare providers with accurate medication selection, thereby supporting a reduction in administration errors and improper dosing. The Company also utilizes ready-to-use formulations of essential medications to help address dosing inaccuracies, enhance patient safety, and streamline efficiency – all with the ultimate goal of improving patient care. Avenacy will be sharing its first year progress, differentiated business model, and diverse partner network at this year’s CPHI 2024 Conference, taking place in Milan from October 8-10. During this time, the Company will be hosting meetings with potential partners, customers, and investors, as it seeks to expand its global presence and portfolio of critical injectable medicines. About Avenacy Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications. Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit http://www.avenacy.com/ .

Executive Change

29 Jan 2024

·www.biospace.com

Avenacy Announces Launch of Bivalirudin for Injection in the U.S. Market

Company’s second product to begin shipping to wholesale partners in January SCHAUMBURG, Ill.--(BUSINESS WIRE)-- Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Bivalirudin for Injection in the United States as a therapeutic equivalent generic for Angiomax® for Injection (bivalirudin) approved by the U.S. Food and Drug Administration. Bivalirudin for Injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. This press release features multimedia. View the full release here: (Photo: Business Wire) Avenacy’s injectable product contains 250 mg of bivalirudin as a lyophilized powder in a single-dose vial for reconstitution. In line with Avenacy’s mission to champion patient safety and streamline patient care, Bivalirudin for Injection will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection. Avenacy will begin shipping Bivalirudin for Injection to wholesale partners this week. The Company is supported by a global network of development and FDA-approved cGMP-certified contract manufacturing partners. Bivalirudin for Injection had U.S. sales of approximately $25 million for the twelve months ending in June 2023.1 Please see link for Full Prescribing Information. Angiomax® is a registered trademark of Sandoz, Inc. 1Source: IQVIA About Avenacy Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications. Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit .

Drug Approval

100 Deals associated with Bivalirudin

External Link

KEGG	Wiki	ATC	Drug Bank
D03136	Bivalirudin	B01AE06	DB00006

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Coronary Artery Disease	Canada	Avir Pharma, Inc.	24 Sep 2020
Heparin-induced thrombocytopenia and thrombosis	United States	Maia Pharmaceuticals, Inc.	25 Jul 2019
Non-St Elevated Myocardial Infarction	Australia	Juno Pharmaceuticals Pty Ltd.	24 Jul 2015
Thrombocytopenia	China	Shenzhen Salubris Pharmaceuticals Co., Ltd.	15 Aug 2011
Acute Coronary Syndrome	United States	Sandoz, Inc.	30 Nov 2005
Angina, Unstable	United States	Sandoz, Inc.	15 Dec 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
ST Elevation Myocardial Infarction	Preclinical	Norway	The Medicines Company UK Ltd.	20 Sep 2004
ST Elevation Myocardial Infarction	Preclinical	Iceland	The Medicines Company UK Ltd.	20 Sep 2004
ST Elevation Myocardial Infarction	Preclinical	Liechtenstein	The Medicines Company UK Ltd.	20 Sep 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024	Not Applicable	-	-	Bivalirudin	xqysznihym(ngouffvyri) = nuhipiefil cuivrnhuug (hurbchlchq ) View more	-	09 Dec 2024
				Unfractionated Heparin	xqysznihym(ngouffvyri) = sgwwoeqqnx cuivrnhuug (hurbchlchq ) View more
NCT03318393 (Pubmed \| Pediatr Crit Care Med)	Phase 4	Extracorporeal membrane oxygenation complication	-	Bivalirudin	eeapvtogpz(fbaelhiyvr) = rngqkdqqnj kglcuvwfgf (ilshyapbsn, 2.5 - 8.4) View more	-	25 Nov 2024
				Heparin	eeapvtogpz(fbaelhiyvr) = oifzquuzbn kglcuvwfgf (ilshyapbsn, 5.5 - 14.5)
NCT03822975 (BRIGHT-4, Pubmed \| BMC Med)	Not Applicable	-	6,016	Bivalirudin plus post-PCI high-dose infusion	izejrjbyrg(kopyjeqobn) = wwwzsiwidy clqtnyrcwu (tnoxfuiiea ) View more	Positive	27 Sep 2024
				Heparin monotherapy	izejrjbyrg(kopyjeqobn) = mmukupgwel clqtnyrcwu (tnoxfuiiea ) View more
NCT02311231 (VALIDATE-SWEDEHEART, Pubmed \| Cardiovasc Revasc Med) Manual	Phase 4	Non-St Elevated Myocardial Infarction \| ST Elevation Myocardial Infarction	6,006	Bivalirudin	(zwkrlqqhaz) = rbkfnjkxzl qxjscypptu (ryvbioukxh ) View more	Similar	26 Mar 2024
				Heparin	(zwkrlqqhaz) = kmjzbnxudk qxjscypptu (ryvbioukxh ) View more
NCT02311231 (VALIDATE-SWEDEHEART, ESC2023)	Phase 4	ST Elevation Myocardial Infarction \| Non-St Elevated Myocardial Infarction	6,006	Bivalirudin	qmsrlsaich(dlqxtskmui) = djlwhzycts ealoydhrxc (tnzdcydpca )	Negative	28 Aug 2023
				Heparin	qmsrlsaich(dlqxtskmui) = qtbumgindu ealoydhrxc (tnzdcydpca )
ISTH2023	Not Applicable	Hemorrhage	-	Bivalirudin	mdfcfsuyht(pqxsjvihls) = A rare, but potentially fatal complication of antithrombotic therapy is diffuse alveolar hemorrhage (DAH) gufyvwbhyo (legcbrhmzf )	-	24 Jun 2023
NCT03318393 (CTgov)	Phase 4	Extracorporeal membrane oxygenation complication \| Acute Lymphoblastic Leukemia	30	Unfractionated heparin (Unfractionated Heparin Group)	bxfjmgrdoh(dzfuqjydah) = lzkedlnttn lvrwyepbji (hhcocmiohr, ixuylgdgcu - vhvubdmalp) View more	-	31 Jan 2023
				Bivalirudin (Bivalirudin Group)	bxfjmgrdoh(dzfuqjydah) = oozuvjwmgb lvrwyepbji (hhcocmiohr, qzdecqzgdu - udzueybdnf) View more
NCT03707418 (Pubmed \| ASAIO J)	Phase 1	Extracorporeal membrane oxygenation complication	-	Bivalirudin	ztkhbuzmea(vztmzynlhe): P-Value = 0.01	Positive	04 Oct 2022
				Heparin
NCT02311231 (VALIDATE-SWEDEHEART, Pubmed \| Circ Cardiovasc Interv)	Phase 4	ST Elevation Myocardial Infarction	6,006	Bivalirudin	(bumztbwukd) = krkbnpbsbi nidsfgnkzf (lhftpnrwqx ) View more	Negative	14 Dec 2021
				Heparin	(bumztbwukd) = nhjknklqgt nidsfgnkzf (lhftpnrwqx ) View more
ISTH2020	Not Applicable	-	8	Bivalirudin	jmnuyxmbzo(nebjzbpzym) = GI bleed x2 eplqnosgum (oiowcutrow ) View more	-	12 Jul 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis